• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Clin Invest. Clinical and immunologic features in severe and moderate Coronavirus Disease 2019

tetano

Editor, Senior Moderator
J Clin Invest. 2020 Mar 27. pii: 137244. doi: 10.1172/JCI137244. [Epub ahead of print]
Clinical and immunologic features in severe and moderate Coronavirus Disease 2019.


Chen G[SUP]1[/SUP], Wu D[SUP]1[/SUP], Guo W[SUP]1[/SUP], Cao Y[SUP]2[/SUP], Huang D[SUP]1[/SUP], Wang H[SUP]1[/SUP], Wang T[SUP]2[/SUP], Zhang X[SUP]1[/SUP], Chen H[SUP]1[/SUP], Yu H[SUP]1[/SUP], Zhang X[SUP]1[/SUP], Zhang M[SUP]3[/SUP], Wu S[SUP]3[/SUP], Song J[SUP]1[/SUP], Chen T[SUP]1[/SUP], Han M[SUP]1[/SUP], Li S[SUP]4[/SUP], Luo X[SUP]5[/SUP], Zhao J[SUP]2[/SUP], Ning Q[SUP]1[/SUP].

Author information




Abstract

BACKGROUND:

Since December 2019, an outbreak of Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in Wuhan, and is now becoming a global threat. We aimed to delineate and compare the immunologic features of severe and moderate COVID-19.
METHODS:

In this retrospective study, the clinical and immunologic characteristics of 21 patients (17 male and 4 female) with COVID-19 were analyzed. These patients were classified as severe (11 cases) and moderate (10 cases) according to the Guidelines released by the National Health Commission of China.
RESULTS:

The median age of severe and moderate cases was 61.0 and 52.0 years, respectively. Common clinical manifestations included fever, cough and fatigue. Compared to moderate cases, severe cases more frequently had dyspnea, lymphopenia, and hypoalbuminemia, with higher levels of alanine aminotransferase, lactate dehydrogenase, C-reactive protein, ferritin and D-dimer as well as markedly higher levels of IL-2R, IL-6, IL-10, and TNF-α. Absolute number of T lymphocytes, CD4+T and CD8+T cells decreased in nearly all the patients, and were markedly lower in severe cases (294.0, 177.5 and 89.0 ? 106/L) than moderate cases (640.5, 381.5 and 254.0 ? 106/L). The expressions of IFN-γ by CD4+T cells tended to be lower in severe cases (14.1%) than moderate cases (22.8%).
CONCLUSION:

The SARS-CoV-2 infection may affect primarily T lymphocytes particularly CD4+T and CD8+ T cells, resulting in decrease in numbers as well as IFN-γ production. These potential immunological markers may be of importance due to their correlation with disease severity in COVID-19.



KEYWORDS:

Cytokines; Immunology; Infectious disease; Respiration; T cells


PMID:32217835DOI:10.1172/JCI137244
Free full text
 
Back
Top